Universal influenza vaccine - Orlance
Alternative Names: MACH-1 universal influenza vaccine - OrlanceLatest Information Update: 03 Jan 2024
At a glance
- Originator Orlance
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Influenza virus infections
Most Recent Events
- 28 Nov 2023 Orlance receives SBIR Phase II grant from National Institutes of Health for MACH-1 delivery platform and a universal influenza vaccine development in Influenza virus infections
- 28 Nov 2023 Preclinical trials in Influenza virus infections (Prevention) in USA (Intradermal)
- 28 Nov 2023 Orlance plans a phase I trial for Influenza virus infections (Prevention) (Intradermal, injection) in 2025